
Natural 9-amino-acid neuropeptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂) — research area: OXTR receptor, social bonding and HPA-axis modulation.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Oxytocin is a nonapeptide — Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, with a disulfide bridge between the two cysteines — synthesized in the hypothalamus and released by the posterior pituitary. It holds a special place in the history of chemistry: it was the first peptide hormone whose structure was determined and synthesized in the laboratory, work for which Vincent du Vigneaud received the 1955 Nobel Prize in Chemistry. It differs from vasopressin in only two amino acids.
It acts on a single receptor, OXTR, coupled to Gq protein and present in the uterus, the mammary gland and numerous brain regions. Its peripheral effects — uterine contraction and milk ejection — have been established for a century; the central ones are the subject of an enormous literature on maternal bonding, prosocial behavior, trust and stress-axis modulation, in rodents, primates and humans. Its plasma half-life is 3 to 5 minutes and, like all peptides, it crosses the blood–brain barrier poorly.
As a medicine (Pitocin, Syntocinon) it is approved for labor induction and postpartum hemorrhage by the intravenous or intramuscular route. Research on behavioral effects mostly uses the intranasal route, and its results are heterogeneous: the largest multicenter trial in autism (NEJM, 2021) found no benefit, and the replicability of small studies on trust and empathy is under discussion. Renova's product is oxytocin for research, not the medicine, and is not suitable for human use.
| Class | Endogenous neuropeptide hormone (oxytocin/vasopressin family) |
| Sequence | Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (9 aa; Cys1–Cys6 disulfide bridge) |
| CAS | 50-56-6 |
| Historical milestone | First peptide hormone synthesized (du Vigneaud, 1953; Nobel 1955) |
| Receptor | OXTR (Gq-coupled); uterus, breast, brain |
| Half-life | 3–5 minutes in plasma |
| Regulatory status | Approved medicine (Pitocin, Syntocinon) for labor and postpartum hemorrhage; Renova product is RUO |
| Stability | Sensitive to heat and to oxidation of the disulfide bridge; keep refrigerated and protected from light |
No. Pitocin and Syntocinon are registered medicines for obstetric use. Renova's vial contains the same molecule as lyophilized research material, independently verified, and it is not intended for human use.
Because oxytocin crosses the blood–brain barrier poorly and lasts only minutes in blood; the nasal route was proposed as a way to reach the brain. How much actually arrives remains debated, and it is one reason studies on trust or empathy have been hard to replicate.
The largest multicenter trial, published in NEJM in 2021 with nearly 300 children and adolescents, found no difference between intranasal oxytocin and placebo in social behavior. Earlier, smaller studies had given positive signals that were not confirmed.
Two amino acids: vasopressin has phenylalanine at position 3 and arginine at 8, where oxytocin has isoleucine and leucine. That small change separates a hormone of labor and lactation from one that regulates blood pressure and water retention; both share an evolutionary origin and partially cross-reactive receptors.
Related reading: Oxytocin: The Bonding Neuropeptide · Kisspeptin-10: The Switch of the Reproductive Axis
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty